Pacquiao inside 8 rounds—Viloria

first_imgMOST READ We are young Bali Pure turns back Valdez, Customs for 1-0 lead in semis Smart’s Siklab Saya: A multi-city approach to esports Brian “Hawaiian Punch” Viloria. Photo by Roy Luarca/INQUIRERLAS VEGAS—Manny Pacquiao’s power will be too much to bear for Jessie Vargas and will eventually be stopped.Brian “Hawaiian Punch” Viloria told this to sportswriters Friday as he appeared at the press room of TheLegend vs The Champ at Wynn hotel.ADVERTISEMENT Taiwan minister boards cruise ship turned away by Japan PLAY LIST 01:31Taiwan minister boards cruise ship turned away by Japan01:33WHO: ‘Global stocks of masks and respirators are now insufficient’01:01WHO: now 31,211 virus cases in China 102:02Vitamin C prevents but doesn’t cure diseases like coronavirus—medic03:07’HINDI PANG-SPORTS LANG!’03:03SILIP SA INTEL FUND “The end will come within eight rounds,” said Viloria, the former unified flyweight champion (World Boxing Associationand World Boxing Organization) as well as the former WBC and International Boxing Federation light flyweight titlist.The 35-year-old Viloria, born in Hawaii of Filipino descent, lost to reigning pound-for-pound king Roman Gonzales in their battle for the WBC flyweight title last year at Madison Square Garden in New York.FEATURED STORIESSPORTSGinebra teammates show love for SlaughterSPORTSWe are youngSPORTSCone plans to speak with Slaughter, agentWith Viloria (36 wins, 5 losses, 2 No Contests, 22 by knockouts) receiving a battering, the referee stopped the lopsided bout at the 2:53 mark of the ninth round.According to Viloria, the 1999 USA Boxer of the Year, he will resume fighting against a yet to be named opponent in January next year. 30 Filipinos from Wuhan quarantined in Capas Don’t miss out on the latest news and information. Chinese-manned vessel unsettles Bohol town EDITORS’ PICK View comments Smart hosts first 5G-powered esports exhibition match in PH BREAKING: Solicitor General asks SC to forfeit ABS CBN’s franchise Brad Pitt wins his first acting Oscar as awards get underway Mainland China virus cases exceed 40,000; deaths rise to 908 Where did they go? Millions left Wuhan before quarantine PH among economies most vulnerable to virus Sports Related Videospowered by AdSparcRead Nextlast_img read more

Misfiring Gunners lack confidence

first_imgIt was Arsenal’s first home loss at this stage of Europe’s elite club competition since Inter Milan won at the Gunners’ old Highbury stadium in 2003.The Emirates faithful responded by booing their team off the pitch at full-time. With frustration growing among the Arsenal fanbase after seven trophy-less years, there are certain to be some difficult questions for Wenger at the club’s annual general meeting on Thursday.Coming just five days after Arsenal produced an equally tame display in a 1-0 loss at struggling Norwich in the Premier League, this lacklustre effort prompted Bould to concede his team was stuck in a rut.“We haven’t played anything like we can, that’s the big disappointment,” Bould said.“We looked jaded. I don’t know why that is. We don’t look confident on the ball at the moment.“It’s not what we are accustomed to. We normally create chances and we need to correct that.“We lack a bit of confidence for whatever reason, but it’s a tough competition. They are a good side.”Bould believes Arsenal’s already fragile confidence is taking a major dent whenever they concede the first goal at present and he hinted changes could be made for Saturday’s clash against QPR.That would likely mean a first appearance for 18 months for England midfielder Jack Wilshere, who is returning from a series of injuries. Alex Oxlade-Chamberlain could also feature after a hip injury.“In the West Ham game we looked really sharp but since returning from the internationals we’ve looked jaded. We need to pick it up again,” Bould said.“Scoring first will be a major plus for us at the minute. We’ve gone behind in the last five games or so and coming back can be hard at times.“One or two might need freshening up on Saturday. Jack and Alex could be available.”Coming up in the group stages is a tricky trip to Schalke up next and an away game at Olympiakos, where Arsenal have lost in the past. Bould acknowledged the Gunners will have to improve to qualify.“Of course they are frustrated. We are as well. We don’t like losing games,” he added.“We have got nine points to play for and wherever we get the points from doesn’t matter. We will perform a damn sight better than this in the next match.”Meanwhile, Schalke coach Huub Stevens claimed his side’s impressive display didn’t mean they were favourites to maintain their one-point lead over Arsenal at the top of the group.“Arsenal is the favourite in this group. When they have all the players fit they are the favourites,” he said.“We have won two games on the road and we have seven points. I have to be happy but there is still a long way to go.“We will have a chance when Arsenal come to Schalke but we must play better than in the first half here.”Although Stevens insisted Schalke’s victory was well deserved, he conceded they should have made their dominance pay much earlier than the final 14 minutes.“At the start we were a bit cagey and had too much respect for Arsenal. We didn’t show enough courage. They were the better team in the first half,” he added.“But we didn’t allow any chances and in the second half we gave the right answer. We can say 2-0 was a deserved win for us.”0Shares0000(Visited 1 times, 1 visits today) 0Shares0000LONDON, England, October 25 – Arsenal assistant manager Steve Bould admitted the Gunners are short of confidence and energy after Schalke inflicted their first home defeat in the Champions League group stages for nine years.Arsene Wenger’s side were out-fought and out-thought by Schalke as late goals from Klaas-Jan Huntelaar and Ibrahim Afellay secured a shock 2-0 victory on Wednesday that took the Germans top of Group B.last_img read more

Contamination scare at NIH leaves clinical trial subjects with tough choice

first_imgSome people enrolled in clinical trials with the U.S. National Institutes of Health (NIH) are continuing the use of experimental drugs despite the possibility the compounds have fungal contaminations.NIH suspended operations yesterday at a facility that makes experimental drugs for the agency’s Clinical Center in the wake of an investigation by the Food and Drug Administration (FDA) that revealed multiple problems that could expose sterile drugs to contamination. Forty-six trials currently underway receive materials from the facility, and NIH is searching for alternate sources of products for about 250 patients involved in the studies. In some instances, however, finding those other sources won’t be possible, and some trials will have to be delayed, says Lawrence Tabak, principal deputy director of NIH.In addition, a few trial subjects, after being informed of the risks, have requested to continue with their experimental treatments made by the now-closed facility. NIH Director Francis Collins has granted exceptions to those whose conditions could be severely compromised if they failed to receive their next scheduled dose. They will be monitored for signs of infection. “Many of them have been taking the products for a while with no untoward effects. The likelihood of infection is small, but we still want to be cautious,” Tabak says.Sign up for our daily newsletterGet more great content like this delivered right to you!Country *AfghanistanAland IslandsAlbaniaAlgeriaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBolivia, Plurinational State ofBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCambodiaCameroonCanadaCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCongo, The Democratic Republic of theCook IslandsCosta RicaCote D’IvoireCroatiaCubaCuraçaoCyprusCzech RepublicDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland Islands (Malvinas)Faroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and Mcdonald IslandsHoly See (Vatican City State)HondurasHong KongHungaryIcelandIndiaIndonesiaIran, Islamic Republic ofIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People’s Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People’s Democratic RepublicLatviaLebanonLesothoLiberiaLibyan Arab JamahiriyaLiechtensteinLithuaniaLuxembourgMacaoMacedonia, The Former Yugoslav Republic ofMadagascarMalawiMalaysiaMaldivesMaliMaltaMartiniqueMauritaniaMauritiusMayotteMexicoMoldova, Republic ofMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorwayOmanPakistanPalestinianPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalQatarReunionRomaniaRussian FederationRWANDASaint Barthélemy Saint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin (French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyrian Arab RepublicTaiwanTajikistanTanzania, United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuela, Bolivarian Republic ofVietnamVirgin Islands, BritishWallis and FutunaWestern SaharaYemenZambiaZimbabweI also wish to receive emails from AAAS/Science and Science advertisers, including information on products, services and special offers which may include but are not limited to news, careers information & upcoming events.Required fields are included by an asterisk(*)“This is a distressing and unacceptable situation,” Collins said in a statement. “The fact that patients may have been put in harm’s way because of a failure to follow standard operating procedures in the NIH Clinical Center’s Pharmaceutical Development Section is deeply troubling. I will personally oversee the steps to protect the safety of patients and remedy the situation as swiftly as possible.”In April, a Clinical Center employee had noticed what appeared to be a fungal contamination in a vial of albumin—used in the administration of the drug interleukin in experimental studies—after being unable to draw the liquid out of the vial. Visual inspection of about 650 vials from the same batch revealed one additional contaminated vial. Six patients from three studies received vials from the same lot, although it’s unclear whether those vials or others were contaminated. At this point, none of the six have developed signs of infection or illness. Following the April episode, an internal review was conducted, says Tabak, which noted several issues with the physical facility. Although the exact timing is unknown, at some point FDA received an anonymous complaint and conducted an unannounced inspection of the NIH facility located on the Bethesda, Maryland, campus between 19 May and 29 May. Their 14-page assessment exposed a number of shortcomings, both physical and operational. An exhaust vent leading from one of the facility’s “clean rooms” to the roof lacked a filter or screen, for example, and flaws in the air handling system could expose sterile drugs to microbial contamination during processing. The report noted deficient cleaning and disinfection processes (insects were found in two of five clean room ceiling light bays), and examples of apparently inadequate employee training (lab employees with clothing that left parts of their face, neck, and arms exposed).To date, all products from the facility have been visually inspected, and no obvious additional contamination was observed. NIH is in the process of sending the products to an outside contracting laboratory for additional testing, which could take several weeks. They are also in the process of contacting and monitoring patients in the remaining 43 studies. Studies of treatments for autoimmune and rare genetic diseases as well as for different forms of cancer are among those potentially affected.A full review using outside experts in engineering, microbial practices, and sterility practices is planned, and NIH is scheduled to provide an interim corrective action plan to FDA by 19 June.last_img read more

Save a panda, save the forest?

first_imgGiant pandas bask in the glow of international stardom, their every live birth or tumble down a hill tweeted by millions. But critics say pandas and other “charismatic megafauna” soak up conservation money and attention, leaving other threatened species in the lurch. Panda proponents have countered that saving the bears can help other animals who share the same habitats—but the evidence has been squishy. Until now. According to a new study, 96% of the panda’s range overlaps with areas identified as the most important “hot spots” for mammals, birds, and amphibians known only to exist in China’s forests, the researchers report online before print in Conservation Biology. In their analysis, the scientists compiled maps on where 132 mammals, 117 birds, and 249 amphibians live in the country, fine-tuning them using elevation data and remote sensing mapping that revealed where forests haven’t been logged. Next, the researchers isolated areas where the number of species in each group was highest—the hot spots—and compared how well those areas overlapped with where pandas occur. In an additional step, they also overlaid maps of China’s system of giant panda national natural reserves to see how well the areas cover these other species, which include the golden snub-nosed monkey, the Tibetan macaque, and the takin (an animal sometimes referred to as a goat-antelope), among others. Surprisingly, they found that the reserves include all of the studied species except for one type of bird. From 2007 to 2014, the number of nature reserves for giant pandas in China doubled from 34 to 67, covering some 33,600 square kilometers. These findings, the scientists say, show that such land conservation matters more than just to the black-and-white bears themselves and the zoo visitors who love them. Still, there are areas where some of these forest animals aren’t protected, the scientists say. To help inform Chinese officials, the researchers identified four areas where future conservation efforts should lie, including in Sichuan province in southwestern China.last_img read more